Pradaxa patent expiration?

When does the Pradaxa patent expire?

As reported on [1]DrugPatentWatch.com, the patent for Pradaxa (dabigatran etexilate), a direct oral anticoagulant used to prevent stroke, blood clots, and other cardiovascular complications in patients with atrial fibrillation, expires on 2029.

However, generic versions of the medication may be available before the patent expires. Companies like Sandoz and Actavis (now Allergan) have already received FDA approval for their generic versions of Pradaxa, which could be launched in the market before the patent expires.

What impact may generic versions have on Pradaxa sales?

According to a report by [2]DrugPatentWatch.com, the availability of generic Pradaxa is expected to have a significant impact on the sales of the medication. The generic version could potentially capture up to 90% of the market share, which could lead to significant revenue losses for the manufacturer, Boehringer Ingelheim.

How does this impact future sales and market share for Pradaxa?

The impending patent expiration of Pradaxa is expected to lead to a decrease in the sales of the medication. However, this could also pave the way for other companies to develop and market generic versions of the medication, which could in turn create new opportunities for sales and market growth.

What alternatives or competitors are available for Pradaxa?

Several direct oral anticoagulants, including Eliquis (apixaban) and Xarelto (rivaroxaban), have already been marketed and are available as alternatives to Pradaxa. Additionally, newer medications like anticoagulant-antiplatelet hybrids have been developed to provide additional options for patients.

Sources:

[1] DrugPatentWatch.com - Dabigatran etexilate Patent Expiration Date
[2] DrugPatentWatch.com - Pradaxa Patent Expiration and Generic Entry